NCT02669173View on ClinicalTrials.gov

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

March 25, 2019

Study Completion Date

August 31, 2025

Conditions
Glioblastoma
Interventions
DRUG

Capecitabine

Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression

DRUG

Bevacizumab

Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER